pre-update Archives

Press Coverage

Pharma Focus America: Big Data Analytics – A Revolution in the Pharmaceutical Industry

In this panel discussion, our panelists will explore how big data analytics is reshaping drug…

CertaraSeptember 11, 2023

Blog

Methods to Increase Signal Finding in Rare Disease Drug Development

The regulatory landscape for drugs to treat rare diseases is being disrupted. Gleaning from several…

CertaraSeptember 8, 2023

Press Coverage

The Inflation Reduction Act’s Impact on Drug Development for Rare Diseases

Despite these wins for many patients, the new law is already impacting the discovery and…

CertaraSeptember 1, 2023

On-Demand Webinar

RAPS Sponsored Webcast: Plain Language Summaries: Understanding the “Why” Behind the Regulations and Guidance

Plain language regulatory requirements have recently come into effect for the EU and UK. This…

CertaraAugust 30, 2023

Publication

Quantification of drug metabolising enzymes and transporter proteins in the paediatric duodenum via LC-MS/MS proteomics using a QconCAT technique

Characterising the small intestine absorptive membrane is essential to enable prediction of the systemic exposure…

CertaraAugust 29, 2023

Announcement

Certara Launches v11.0 of SEND Explorer

Delivers advanced data analysis and visualization capabilities to support nonclinical scientists PRINCETON, N.J.— August 28,…

CertaraAugust 28, 2023

Blog

Payers’ reaction to the IRA’s Medicare Part D Redesign

On August 16, 2022, President Biden signed the Inflation Reduction Act of 2022 (IRA) into…

CertaraAugust 25, 2023

Poster

AMCP Poster – A survey-based analysis of the determinants of management in traditionally unmanaged categories of oncology and rare diseases

CertaraAugust 25, 2023

Publication

Development and Verification of a Japanese Pediatric Physiologically Based Pharmacokinetic Model with Emphasis on Drugs Eliminated by Cytochrome P450 or Renal Excretion

Physiologically based pharmacokinetic (PBPK) models are useful in bridging drug exposure in different ethnic groups,…

CertaraAugust 21, 2023

Publication

Development and application of a PBPK modeling strategy to support antimalarial drug development

As part of a collaboration between Medicines for Malaria Venture (MMV), Certara UK and Monash…

CertaraAugust 18, 2023

pre-update

Pharma Focus America: Big Data Analytics – A Revolution in the Pharmaceutical Industry

Methods to Increase Signal Finding in Rare Disease Drug Development

The Inflation Reduction Act’s Impact on Drug Development for Rare Diseases

RAPS Sponsored Webcast: Plain Language Summaries: Understanding the “Why” Behind the Regulations and Guidance

Quantification of drug metabolising enzymes and transporter proteins in the paediatric duodenum via LC-MS/MS proteomics using a QconCAT technique

Certara Launches v11.0 of SEND Explorer

Payers’ reaction to the IRA’s Medicare Part D Redesign

AMCP Poster – A survey-based analysis of the determinants of management in traditionally unmanaged categories of oncology and rare diseases

Development and Verification of a Japanese Pediatric Physiologically Based Pharmacokinetic Model with Emphasis on Drugs Eliminated by Cytochrome P450 or Renal Excretion

Development and application of a PBPK modeling strategy to support antimalarial drug development

Newsletter sign up

Quick links

Solutions

Contact